Overview

A Pilot Bioequivalence Study of Pomalidomide

Status:
Not yet recruiting
Trial end date:
2025-03-15
Target enrollment:
Participant gender:
Summary
Pilot bioequivalence trial of two pomalidomide formulations consisting in 4 mg oral capsules.
Phase:
Phase 1
Details
Lead Sponsor:
Megalabs
Treatments:
Pomalidomide
Thalidomide